TICKERNERD
Menu
BMRABMRAHealthcare · Medical Devices

BMRA Stock Forecast: Biomerica, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.24
+0.45% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$10.3M
Ticker Nerd rank
17 / 100
Median analyst target
—
Analysts covering
1
Revenue$875K+16.8% y/y
Operating income−$1.5M
Net income−$1.1M
Free cash flow−$894K
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.9%
1M
+42.7%
YTD
−11.1%
1Y
−24.1%
From 52W high
−30.0%
From 52W low
+50.3%
$1.49
$3.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biomerica, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Growth
57
Volatility
44
Momentum
37
Accruals
26
Revisions
25
Value
25
Quality
17
Issuance
8

Size (93): Smaller than most of the companies we track.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26BMRA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2020Aegis CapitalMaintainsBuy$13 → $11
4 Sept 2020Aegis CapitalMaintainsBuy—
21 Aug 2020Aegis CapitalInitiatesBuy—
17 Dec 2018B. Riley FBRMaintainsBuy—
17 Dec 2018B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BMRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Biomerica, Inc. returned −24.1% against +17.5% for the S&P 500, dividends included.

BMRA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26BMRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Biomerica, Inc. (BMRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
2.7×

Cheaper than 36% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
16.8%

Higher than 65% of US stocks

Earnings growth (YoY)
16.8%

Higher than 55% of US stocks

Gross margin
−8.1%

Higher than 3% of US stocks

Operating margin
−175.2%

Higher than 11% of US stocks

Net margin
−84.8%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−112.1%

Higher than 12% of US stocks

Return on assets
−52.3%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biomerica, Inc. (BMRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biomerica, Inc. has a market value of $10.3M and an enterprise value of $11.4M.

  • Revenue in the twelve months to 31 May 2026: $4.5M. The latest quarter grew 16.8% year on year.

  • Net income over the same four quarters: −$3.8M, a −84.8% net margin.

  • Free cash flow in the twelve months to 31 May 2026: −$3.4M.

  • Shares outstanding: 3.1M.

  • Trailing P/E: −0.9×; forward P/E: 5.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Biomerica, Inc. employs 50 people — $89K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

BMRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BMRABiomerica, Inc.$10.3M
17
IRIXIRIDEX Corp.$11.3M
80
SINTSINTX Technologies, Inc.$11.4M
27
ADGMAdagio Medical Holdings, Inc.$11.9M
37
PMIPicard Medical, Inc.$12.5M
25
WOKWORK Medical Technology Group Ltd.$8.4M
16
HSCSHeartSciences, Inc.$13.2M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biomerica, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMRA news & analysis

Biomerica Reports Fiscal 2026 Year-End Financial Results

GlobeNewsWire · 1 Sept 2026neutral

Biomerica, Inc. reported its financial results for the fiscal year ended May 31, 2026, in a news release dated September 1, 2026. The company disclosed the results via GlobeNewswire from its Irvine, California headquarters.

Why it matters — This announcement provides BMRA shareholders with the company's official year-end financial performance data, a key reporting event for monitoring the company's fiscal health.

Biomerica Announces $2.23 Million Financing

GlobeNewsWire · 27 Aug 2026neutral

Biomerica announced it entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of its common stock at $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the company.

Why it matters — BMRA watchers would care because the private placement provides additional capital to the company through the issuance of new shares.

FAQ

Frequently asked questions about BMRA stock

Is BMRA stock a buy right now?

Of the 1 analysts covering Biomerica, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biomerica, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMRA?

As at 12 Sept 2026, Biomerica, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the BMRA stock forecast for 2030?

No analyst covering Biomerica, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRA are extrapolating price history, which says nothing about the business.

How has BMRA stock performed over the past year?

Biomerica, Inc. returned -24.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biomerica, Inc. do?

Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products.

What is the latest news on BMRA?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Biomerica Reports Fiscal 2026 Year-End Financial Results". Biomerica, Inc. reported its financial results for the fiscal year ended May 31, 2026, in a news release dated September 1, 2026. The company disclosed the results via GlobeNewswire from its Irvine, California headquarters.

Company

About Biomerica, Inc.

Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products. The company’s portfolio centers on in-vitro diagnostic solutions used in point-of-care settings, physicians’ offices, and hospital and clinical laboratories. Its products address a range of medical conditions, with emphasis on gastrointestinal and inflammatory diseases, food intolerances, diabetes, and other diagnostic applications. Biomerica Inc. also serves clinical laboratory, physician office, home testing, and over-the-counter channels, supporting early detection and treatment decisions across multiple healthcare environments. Based in Irvine, California, the company operates as a specialized healthcare provider with a market presence in both diagnostic testing and therapeutic product development.

CEO Mr. Zackary S. Irani · 50 employees · United States · https://www.biomerica.com